Mikhail Blagosklonny is a renowned professor of Oncology who has revolutionized cancer and aging research fields. He serves as a professor of oncology at the Roswell Cancer Institute. Cancer and aging research fields have gained a lot of interest after the increase in the number of aged people dying of cancer. Mikhail Blagosklonny has been very instrumental in the pursuit of cancer treatment and anti-aging research.
Professor Blagosklonny is honored worldwide for his theory of TOR signaling. In his theory, he formulated TOR signaling by using Rapamycin, which is a prominent cancer drug that can be used to prolong human life by reducing aging rates. Globally, he is recognized as one of the major advocates of Rapamycin in human life extension research. Rapamycin is used to coat coronary stents during organ transplants to reduce chances of organ rejection.
Mikhail Blagosklonny attended the First Pavlov State University of St. Petersburg where he earned his MD in internal medicine and Ph.D. in experimental medicine and cardiology. He served as an associate professor at the New York Medical College in 2002; he was later appointed to serve as a senior scientist at Ordway Research Institute, Albany, NY. In 2009, he joined Roswell Park Cancer Institute where he serves as a professor of oncology. At Roswell, he is involved in developing therapies to protect healthy cells from being damaged by aging elements. Follow Mikhail on Loop
In most of his research, he targets cancer, anti-ageing drugs, and biogerontology. With the number of degenerative conditions such as cancer and old age increasing, Blagosklonny research remains one of the most valuable aspects of the future. It is estimated that over two billion people will be aged above 60 by 2050. At this age, cells begin to degenerate and chances of being diagnosed with cancer are higher. Therefore, Blagosklonny’s research will be the much-awaited breakthrough in life extension.
Blagosklonny is also a distinguished author. He has published over 250 book chapters, articles, and cancer reviews. He is also the editor-in-chief of Cell Cycle, Oncotarget, and Aging. He was appointed to serve as an associate editor for The American Journal of Pathology, Cell Death and Differentiation, Cancer Biology and Therapy, and International Journal of Cancer. Visit ResearchGate.Net to learn more about Mikhail’s latest work.